Phenotypes associated with this allele

• Allele Symbol: Gt(ROSA)26Sor^{tm2(H1/tetO-RNAi:Kdm1a)Arte}
• Allele Name: targeted mutation 2, TaconicArtemis
• Allele ID: MGI:5468804
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
ht1	Gt(ROSA)26Sor^tm2(H1/tetO-RNAi:Kdm1a)Arte/Gt(ROSA)26Sor^+	involves: C57BL/6	MGI:5469737

Genotype
MGI:5469737

ht1

• Allelic Composition: Gt(ROSA)26Sor^{tm2(H1/tetO-RNAi:Kdm1a)Arte}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

hematopoietic system

hematopoietic system phenotype ( J:192055 )

N • following withdrawal of doxycycline, peripheral blood parameters are normalized

abnormal granulocyte differentiation ( J:192055 )

• perturbed terminal granulopoiesis with a 2-fold increase in granulo-monocytic progenitors in doxycycline-treated mice

increased hematopoietic stem cell proliferation ( J:192055 )

• increased proliferation and reduced quiescent cells in doxycycline-treated mice

enlarged spleen ( J:192055 )

• in doxycycline-treated mice

abnormal erythropoiesis ( J:192055 )

• expanded early but inhibited terminal erythropoiesis in doxycycline-treated mice

• splenic stress erythropoiesis with insufficient terminal erythropoiesis doxycycline-treated mice

anemia ( J:192055 )

• in doxycycline-treated mice

abnormal bone marrow cell morphology/development ( J:192055 )

• expansion of pre-megakaryoerythroid progenitors in doxycycline-treated mice

abnormal monocyte differentiation ( J:192055 )

• enhanced monopoiesis with a 3-fold increase in monocyte/dendritic progenitors in doxycycline-treated mice

abnormal megakaryocyte morphology ( J:192055 )

• dysmorphic with marginalized hyperlobulated nuclei and reduced cytoplasmic volume in doxycycline-treated mice

increased megakaryocyte cell number ( J:192055 )

• 7-fold in the bone marrow of doxycycline-treated mice

decreased erythroid progenitor cell number ( J:192055 )

• reduction in marrow erythroid precursors in doxycycline-treated mice

increased erythroid progenitor cell number ( J:192055 )

• expansion of pre-erythroid colony-forming unit progenitors and colony forming unit erythroid in doxycycline-treated mice

abnormal megakaryocyte progenitor cell morphology ( J:192055 )

• expanded in doxycycline-treated mice

abnormal proerythroblast morphology ( J:192055 )

• expansion of proerythroblasts in doxycycline-treated mice

abnormal platelet morphology ( J:192055 )

• fewer large in doxycycline-treated mice

increased mean platelet volume ( J:192055 )

• in doxycycline-treated mice

increased leukocyte cell number ( J:192055 )

• slightly in doxycycline-treated mice

increased hematopoietic stem cell number ( J:192055 )

• in doxycycline-treated mice

• however, bone marrow cellularity is normal

cellular

abnormal granulocyte differentiation ( J:192055 )

• perturbed terminal granulopoiesis with a 2-fold increase in granulo-monocytic progenitors in doxycycline-treated mice

abnormal monocyte differentiation ( J:192055 )

• enhanced monopoiesis with a 3-fold increase in monocyte/dendritic progenitors in doxycycline-treated mice

increased hematopoietic stem cell proliferation ( J:192055 )

• increased proliferation and reduced quiescent cells in doxycycline-treated mice

homeostasis/metabolism

increased circulating erythropoietin level ( J:192055 )

• 7-fold in doxycycline-treated mice

immune system

abnormal granulocyte differentiation ( J:192055 )

• perturbed terminal granulopoiesis with a 2-fold increase in granulo-monocytic progenitors in doxycycline-treated mice

abnormal monocyte differentiation ( J:192055 )

• enhanced monopoiesis with a 3-fold increase in monocyte/dendritic progenitors in doxycycline-treated mice

enlarged spleen ( J:192055 )

• in doxycycline-treated mice

increased leukocyte cell number ( J:192055 )

• slightly in doxycycline-treated mice

growth/size/body

enlarged spleen ( J:192055 )

• in doxycycline-treated mice